Dopamine Agonists
Dopamine Agonists - Related Videos
05:01
Measuring Dopamine Uptake in Mouse Brain Synaptosomes Using Radiolabeled Dopamine
0 Views •
2025
This video demonstrates the assessment of dopamine uptake in synaptosomes harvested from mouse brains. It outlines steps for preparing synaptosomes for dopamine uptake via dopamine transporters, treating them with varying concentrations of radiolabeled dopamine, isolating the synaptosomes, and measuring radioactivity to quantify dopamine uptake.
02:11
Formulating a Dopamine-Loaded Exosome Carrier System
0 Views •
2025
Source: Yavuz, B., et al. Formulating and Characterizing an Exosome-based Dopamine Carrier System. J. Vis. Exp. (2022)This video demonstrates the formulation of dopamine-loaded exosomes, focusing on saponin-induced membrane permeabilization to enhance dopamine encapsulation within exosomes.
14:21
Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
0 Views •
Cited by 15 •
2013
We present a novel PET imaging approach for capturing dopamine fluctuations induced by cigarette smoking. Subjects smoke in the PET scanner. Dynamic PET images are modeled voxel-by-voxel in time by lp-ntPET, which includes a time-varying dopamine term. The results are 'movies' of dopamine fluctuations in the striatum during smoking.
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
0 Views •
Cited by 10 •
2011
A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor activation.
04:04
Isolation and Culture of Primary Embryonic Mouse Midbrain Dopamine Neurons
0 Views •
2025
The video demonstrates the process of isolating and culturing dopamine neurons from the midbrain of mouse embryos. The isolated ventral midbrain floors are dissociated using enzymes. The resulting dopamine neurons are harvested and transferred into micro-islands inside multi-well plates. The cells are incubated with a dopamine neuron medium to maintain the cells at a high density inside the micro-islands.
FAQs
Receptor subtype matters because D1-like and D2-like receptors connect dopamine stimulation to intracellular signaling in different receptor populations. Activating one receptor group rather than the other can therefore influence which dopaminergic functions are affected. This distinction helps pharmacologists relate a drug’s receptor activity to outcomes involving movement, endocrine regulation, reward, or cognition.
Direct agents stimulate dopamine receptors themselves, whereas indirect agents increase receptor stimulation by promoting dopamine release or reducing dopamine breakdown. Both approaches can strengthen dopaminergic signaling, but they act at different points in the pathway. This mechanistic distinction provides a basis for comparing drug actions and interpreting why their physiological effects may not be identical.
Dopamine participates in several functions, including movement, endocrine regulation, reward, and cognition. Increasing signaling can therefore improve a disorder involving one dopaminergic pathway while also affecting other functions. The same broad distribution helps explain reported reactions such as nausea, low blood pressure, hallucinations, and impulse-control problems, rather than limiting effects to the intended target.
Clinical effects depend on which dopaminergic pathway is being targeted and whether the medication acts directly at receptors or indirectly by increasing available dopamine signaling. Receptor subtype activity also matters. These variables help explain why the same general pharmacological strategy can be used across movement, endocrine, and selected neurological conditions while producing different benefits and tolerability concerns.
Clinicians use these medications in Parkinson’s disease, hyperprolactinemia, and selected cases of restless legs syndrome. Their relevance differs by condition: dopaminergic signaling is addressed in a movement disorder, an endocrine disorder, or a neurological syndrome. The overview also identifies adverse reactions, so treatment context includes weighing intended effects against nausea, low blood pressure, hallucinations, or impulse-control problems.
Pharmacology evaluates how receptor activation changes intracellular signaling and how those changes relate to clinical outcomes. It also considers whether a compound acts directly on dopamine receptors or indirectly by increasing dopamine stimulation. Connecting molecular action with movement, endocrine regulation, reward, cognition, and adverse reactions allows investigators to interpret both therapeutic effects and unwanted responses.
These drugs are relevant when altered dopamine signaling contributes to the condition being treated. In Parkinson’s disease, their use relates to movement; in hyperprolactinemia, it relates to endocrine regulation; and in selected restless legs syndrome cases, it addresses a neurological context. Their broader pharmacological effects require attention because dopamine pathways also influence reward and cognition.